David Mitchell

Founder and President Patients for Affordable Drugs

Morning Keynote: The Patient Perspective

INSTITUTE 2 HEALTH POLICY FORUM



1

PATIENTS FOR AFFORDABLE DRUGS

My Battle with Blood Cancer

 Diagnosed with Multiple Myeloma in 2010

 Cancer brought me face-to-face with high price drugs





INSTITUTE § HEALTH POLICY FORUM

Patient Voices Absent on Drug Pricing

 83 percent of patient groups with funding over \$7.5 million receive take money from drug corporations


 Some, including IMF, have activated patients against proposals aimed at lowering drug prices





KAISER PERMANENTE

Patients for Affordable Drugs



Independent: We don't accept funding from any organizations that profit from the development or distribution of prescription drugs

INSTITUTE E HEALTH POLICY FORUM



Stories of Pain and Struggle




INSTITUTE & HEALTH POLICY FORUM

We have collected 13,000 stories and 82,000 email addresses

KAISER PERMANENTE


6

Mobilizing Patients: State Legislation





State Legislation Successes



Mobilizing Patients: Coming to D.C.



INSTITUTE E HEALTH POLICY FORUM



Mobilizing Patients: Press and Storytelling



KAISER PERMANENTE

INSTITUTE 2 HEALTH POLICY FORUM

This Congress: The CREATES Act

- Wide spectrum of support
 - 21 bipartisan Senate co-sponsors
 - 16 bipartisan House co-sponsors
- We made a real push along with allies
- Pharma-especially Celgene-dug in
- Despite overwhelming support, Congress does nothing to lower drug prices

Administration Actions

- Benefit design: Tinkering around the edges without getting at retail prices
- PBMS: Reducing take of middlemen
- Part D: POS Rebate & capping out of pocket at the catastrophic level?
 - Must be careful with premium impact when limiting oop



The Future Directions: Patent Reform

- Perhaps best opportunity for bipartisan action to lower retail prices
- Patent reform includes:
- REMS abuse, sovereign immunity, product hopping, evergreening, sham citizen petitions, patent thickets
- There is growing energy to organize, focus and confront these issues

Future Directions: Taxpayer IP



NIH Funding Behind All New Drug Approvals by FDA from 2010-2016

- Taxpayers are paying twice for new drugs
 - Once to develop new drugs and again paying prices based on a false claim of high risk
- These drugs will bankrupt families and our system
- We need a national dialogue about this
- NIH meeting & follow up

Future Directions: New Therapies/CAR-T

- CAR-T is the poster child
- NIH invested \$200 million in CAR-T
- At \$475,000 Novartis will realize 65% profit
 - Right price closer to \$160,000
- We will keep pushing on this issue for the long haul



PATIENTS FOR AFFORDABLE DRUGS NOW

- We have resources to do more direct state and federal lobbying
- We plan to engage in some political campaigns to highlight and boost the issue of drug pricing for the new Congress and statehouses
- Stay tuned



E 🖇 HEALTH POLICY FORUM

Contact and Resources:



David@patientsforaffordabledrugs.org

@p4ad_ @DavidP4AD



Patients For Affordable Drugs



INSTITUTE 2 HEALTH POLICY FORUM

